Company intelligence / Profile preview

Agna Biopharmaceutical

Guangdong Sheng, Chinaagnahealthcare.com ↗

Ownership: Private
Development stage: Commercial

Overview

Agna Biopharmaceutical has developed mRNA vaccines for COVID‑19, including delta/omicron variants. Its lead program RBMRNA‑176 is in Phase 2 clinical trials for COVID‑19, with other mRNA vaccine candidates also advancing through early-stage clinical development. The company possesses proprietary RNAi and LNP delivery platforms. No detailed efficacy or safety results are publicly summarized as of the latest update.

Therapeutic areas: Infectious Diseases
Modalities: mRNA-based drugsRNA therapyVaccineLipid nanoparticle delivery therapy
Industry: Biotech

Drug pipeline

2 assets

RBMRNA-176

1 more asset in the full pipeline.

Request access →

Partnerships

Guangzhou Ribobio Co., Ltd.Guangzhou Medical University

Beyond the preview

Go deeper on Agna Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Agna Biopharmaceutical.

Explore the full profile